The drug is selling ok but not nearly as well as (I think) most of the reps expected. As far as company guidance goes, they have done zero to partner or sell rights to raise capital or advance the program. Proof enough for me the management has to go.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.